Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Xeris Biopharma Holdings does not have enough data to calculate 10-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Xeris Biopharma Holdings 10-Year ROIIC % Related Terms
Xeris Biopharma Holdings 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2B30 vs HROW, PRGO, PAHC: 10-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's 10-Year ROIIC % falls into.
Xeris Biopharma Holdings's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 21.261 (Dec. 2025) - (Dec. 2015) )
/
( 185.371 (Dec. 2025) - (Dec. 2015) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Xeris Biopharma Holdings (FRA:2B30) has a 10-Year ROIIC % of -31.48 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Xeris Biopharma Holdings and its competitors. According to the industry distribution chart, Xeris Biopharma Holdings ranks #751 out of 858 companies in the Drug Manufacturers industry, placing it in the top 87.5%.
Is Xeris Biopharma Holdings' 10-Year ROIIC % too high?
Xeris Biopharma Holdings' current 10-Year ROIIC % is -31.48. Based on the distribution chart, Xeris Biopharma Holdings ranks #751 out of 858 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' 10-Year ROIIC % compare to HROW and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #751 out of 858 companies for 10-Year ROIIC %. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median 10-Year ROIIC % is 4.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.26, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current 10-Year ROIIC % is -31.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.48, compared to a current price of €6.94 — trading 54.8% above its estimated fair value. The current 10-Year ROIIC % is -31.48. Xeris Biopharma Holdings' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current 10-Year ROIIC % is -31.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €6.94 is trading 54.8% above its estimated GF Value™ of €4.48.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for FRA:2B30:
10-Year ROIIC %: -31.48
GF Value™: €4.48 vs. price of €6.94 (54.8% above fair value)
No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score
Get the complete analysis for FRA:2B30
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2B30 has been successfully added to your 
